Abstract: A presence detection system includes a support layer operable to act as an underlying surface for supporting object(s), a sensor layer disposed beneath the support layer and operable to output readings indicating the presence of object(s) supported on the support layer and a controller for receiving the presence readings from the sensor layer and determining, based on the readings, an indicator of the occupancy status and/or an occupancy level of the support layer. The presence detection system can be used within an access gate system whereby the access gate is operated to a blocking position upon the presence detection system detecting more than one human supported on the support layer, this operation overriding a reading of an authenticated user token. The presence detection system can also be used within an elevator system wherein the elevator door subsystem and the elevator displacement subsystem are controlled based on an occupancy level detected by the detection system.

Abstract: A method for preparing a material having an Sn:Sb intermetallic phase includes at least the steps of mixing chemical elements Sn and Sb, and treating the mixture with microwaves. An electrode is manufactured by using the material having an Sn:Sb intermetallic phase; forming the material in a form of powder; mixing the powder with carbon, a binder and a solvent to form an ink; coating a current collector with the ink; and drying the electrode.

Abstract: Inflammation is a prominent feature of ischemia-reperfusion injury (IRI) characterized by leukocyte infiltration and renal tubular injury. However, the signals that initiate these events remain poorly understood. The inventors identify the nuclear alarmin interleukin (IL)-33 as an initiation factor of tissue injury and also as a major amplification factor of the innate immune response triggered by experimental kidney ischemia-reperfusion in mice. In mice lacking IL-33, IRI is reduced, as attested by early decreased tubular cell injury, and by subsequent decreased infiltration of IFN-?/IL-17A-producing neutrophils and preservation of renal functions. These findings led the inventors to propose that endogenous IFN-33 contributes to kidney IRI by promoting iNKT cell recruitment and cytokine production, resulting in neutrophil infiltration and activation at the injury site. Accordingly, the present invention relates to antagonists of IL-33 for use in methods for preventing ischemia reperfusion injury in an organ.

Abstract: A presence detection system includes a support layer operable to act as an underlying surface for supporting object(s), a sensor layer disposed beneath the support layer and operable to output readings indicating the presence of object(s) supported on the support layer and a controller for receiving the presence readings from the sensor layer and determining, based on the readings, an indicator of the occupancy status and/or an occupancy level of the support layer. The presence detection system can be used within an access gate system whereby the access gate is operated to a blocking position upon the presence detection system detecting more than one human supported on the support layer, this operation overriding a reading of an authenticated user token. The presence detection system can also be used within an elevator system wherein the elevator door subsystem and the elevator displacement subsystem are controlled based on an occupancy level detected by the detection system.

Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, to be used in the prevention or treatment of light-induced damage and/or a degeneration of the retina in a patient.

Abstract: Method for preparing an intermetallic material SnSb, said method comprising at least the following steps: a/mixing the precursors Sn and Sb, b/treating the mixture from step a/with microwaves. The intermetallic phase obtained may be used for the manufacture of electrodes.

Abstract: The present invention discloses novel active polypeptide fragments of human IL-33 corresponding to natural forms generated by the proteases of human neutrophils (cathepsin G, elastase 2, proteinase 3), as well as the use thereof as a drug, in particular for the treatment of infectious diseases, inflammatory diseases, atherosclerosis, cardiovascular diseases, obesity, or cancer.

Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, to be used in the prevention or treatment of light-induced damage and/or a degeneration of the retina in a patient.

Abstract: The present invention relates to yeast cells for use in the prevention or treatment of gastric or intestinal ulcers.

Abstract: The present invention concerns a method of inducing IL-2-free proliferation of ?? T cells using a combination of a ?? T cell activator and IL-33 for use in therapy of infection, cancer, autoimmunity as well as other diseases.

Abstract: The present invention discloses novel active polypeptide fragments of human IL-33 corresponding to natural forms generated by the proteases of human neutrophils (cathepsin G, elastase 2, proteinase 3), as well as the use thereof as a drug, in particular for the treatment of infectious diseases, inflammatory diseases, atherosclerosis, cardiovascular diseases, obesity, or cancer.

Abstract: The present invention relates to a pharmaceutical composition comprising as active substances: at least one compound of the following general formula (I): and at least one inhibitor of type 2 cyclooxygenase (COX-2), notably for use in the prevention or treatment of pain.

Abstract: The present invention relates to a pharmaceutical composition comprising as active substances: at least one compound of the following general formula (I): and at least one compound of the following general formula (V): especially for its use in the prevention or treatment of pain.

Abstract: The present invention relates to the use of at least one compound of formula (I) below: or at least one of the pharmaceutically acceptable salts thereof, for the preparation of a medicament intended for the prevention or for the treatment of cerebral edemas.

Abstract: This invention relates to the use of at least one compound of the following formula (I): or its pharmaceutically acceptable salts, for the preparation of a medicinal compound having neuroprotective activity intended to prevent or treat neurone deteriorations.

Abstract: The present invention relates to yeast cells for use in the prevention or treatment of gastric or intestinal ulcers.

Abstract: The present invention relates to a pharmaceutical composition comprising as active substances: at least one compound of the following general formula (I): and at least one inhibitor of type 2 cyclooxygenase (COX-2), notably for use in the prevention or treatment of pain.

Abstract: A circuit for providing a bandgap voltage. The circuit includes a classic bandgap reference voltage generation circuit including first end second serially connected transistors acting as a current mirror to another portion of the classical bandgap reference circuit and being coupled between a supply voltage Vdd and an output resistor. The circuit also includes a current trimming circuit coupled in parallel with the classical bandgap reference generation circuit including a fixed element portion including a plurality of transistors and a switch portion including a plurality of switches. Each of the plurality of transistors is coupled to the supply voltage Vdd and to a one of the plurality of switches and each switch includes a fuse.

Abstract: Described herein are chemokine-binding domains of THAP-family polypeptides and pharmaceutical compositions which include a polypeptide comprising a chemokine-binding domain of a THAP-family polypeptide. Also disclosed are methods of binding chemokines, inhibiting the activity of chemokines, detecting chemokines, and reducing the symptoms associated with a chemokine mediated or influenced condition by contacting the chemokine with an agent that includes a polypeptide comprising a chemokine binding domain of a THAP-family polypeptide.

Abstract: Described herein are chemokine-binding domains of THAP-family polypeptides and pharmaceutical compositions which include a polypeptide comprising a chemokine-binding domain of a THAP-family polypeptide. Also disclosed are methods of binding chemokines, inhibiting the activity of chemokines, detecting chemokines, and reducing the symptoms associated with a chemokine mediated or influenced condition by contacting the chemokine with an agent that includes a polypeptide comprising a chemokine binding domain of a THAP-family polypeptide.